Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
$2.19
-2.7%
$2.64
$1.87
$11.66
$4.26M-0.021.45 million shs35,931 shs
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
$1.02
$0.97
$0.80
$2.18
$4.35M0.96312,159 shs49,600 shs
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$0.01
+4.3%
$0.01
$0.01
$0.02
$1.15M-0.99409,856 shs1.96 million shs
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
$2.92
-2.3%
$3.37
$2.20
$5.27
$4.61M2.3147,840 shs9,209 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
-2.67%-7.20%-15.77%-41.13%-69.47%
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
0.00%0.00%+4.94%+3.03%-8.93%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
+4.30%+5.43%+4.30%+5.43%-3.00%
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
-2.34%-1.68%-21.93%+0.34%-11.25%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
1.1754 of 5 stars
0.02.00.04.32.41.70.0
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
1.0222 of 5 stars
0.04.00.00.02.91.70.0
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
1.7636 of 5 stars
0.05.00.04.82.50.00.0
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
0.7355 of 5 stars
0.03.00.00.02.50.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
0.00
N/AN/AN/A
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
0.00
N/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.00
N/AN/AN/A
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
$1.33M3.11N/AN/A($11.37) per share-0.19
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/AN/AN/AN/A$0.73 per shareN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$11.39M0.10N/AN/A($2.64) per share0.00
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
$2.50M1.80N/AN/A$2.88 per share1.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
-$7.90M-$19.96N/AN/A-647.29%N/A-50.13%8/18/2025 (Estimated)
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
-$5.26M-$1.10N/AN/AN/A-164.79%-71.12%9/15/2025 (Estimated)
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$52.98M-$0.05N/AN/A-46.42%-91.97%-61.93%N/A
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
-$3.96M-$2.38N/AN/AN/A-126.08%-54.56%-47.28%N/A

Latest EVFM, XBIO, CMND, and ALBT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
N/A-$2.02N/A-$6.22N/AN/A
8/12/2025Q2 2025
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
-$0.64-$0.45+$0.19-$0.45$0.48 million$0.59 million
6/12/2025Q2 2025
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/A-$0.16N/A-$0.16N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
N/AN/AN/AN/AN/A
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/AN/AN/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/AN/AN/AN/AN/A
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
N/A
0.19
0.19
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/A
1.74
1.74
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/A
0.11
0.09
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
N/A
5.93
8.20

Institutional Ownership

CompanyInstitutional Ownership
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
1.42%
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
96.05%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.22%
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
15.12%

Insider Ownership

CompanyInsider Ownership
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
37.30%
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.01%
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
14.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
51.89 million1.19 millionNot Optionable
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/A4.27 millionN/ANot Optionable
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
120118.66 million113.12 millionNot Optionable
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
41.54 million1.32 millionNot Optionable

Recent News About These Companies

Xenetic Biosciences (XBIO) to Release Earnings on Tuesday
Xenetic Biosciences (XBIO) Receives a Hold from H.C. Wainwright

New MarketBeat Followers Over Time

Media Sentiment Over Time

Avalon GloboCare stock logo

Avalon GloboCare NASDAQ:ALBT

$2.19 -0.06 (-2.67%)
Closing price 08/14/2025 04:00 PM Eastern
Extended Trading
$2.24 +0.05 (+2.28%)
As of 08/14/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.

Clearmind Medicine stock logo

Clearmind Medicine NASDAQ:CMND

$1.02 0.00 (0.00%)
Closing price 08/14/2025 04:00 PM Eastern
Extended Trading
$1.01 -0.01 (-0.49%)
As of 08/14/2025 06:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Evofem Biosciences stock logo

Evofem Biosciences NASDAQ:EVFM

$0.0097 +0.00 (+4.30%)
As of 08/14/2025 03:59 PM Eastern

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Xenetic Biosciences stock logo

Xenetic Biosciences NASDAQ:XBIO

$2.92 -0.07 (-2.34%)
Closing price 08/14/2025 03:55 PM Eastern
Extended Trading
$2.83 -0.09 (-3.08%)
As of 08/14/2025 04:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.